Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04729387 · ClinicalTrials.gov registry record · Phase 3
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 358
- Enrollment target
NCT04729387 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 358 participants.
The verdict
NCT04729387, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 358 participants
- Enrollment target
Study Summary
The objective of this study was to assess the efficacy and safety of the combination of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian cancer, with no germline BRCA mutation detected.
Interventions
- DRUG Olaparib
- DRUG Paclitaxel
- DRUG Alpelisib
- DRUG Pegylated liposomal doxorubicin (PLD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 358 participants |
| Start Date | 2021-07-22 |
| Est. Completion | 2026-01-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04729387
The ClinicalTrials.gov registry entry for NCT04729387 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 358 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Olaparib is the first listed.
NCT04729387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04729387 about?
NCT04729387 is a clinical study titled "Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected". The objective of this study was to assess the efficacy and safety of the combination of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian cancer, with no germline BRCA mutation detected.
What is the current status of trial NCT04729387?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 358 participants. The study started on 2021-07-22. Estimated completion is 2026-01-19.
What interventions are being tested in trial NCT04729387?
The interventions under investigation include: Olaparib (DRUG), Paclitaxel (DRUG), Alpelisib (DRUG), Pegylated liposomal doxorubicin (PLD) (DRUG).
Who is sponsoring clinical trial NCT04729387?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.